Document 0566
 DOCN  M9650566
 TI    Unusual course of the hepatitis C virus infection in one patient
       diagnosed of common variable immunodeficiency.
 DT    9605
 AU    Munoz FJ; de la Calle A; Gimenez MJ; Gonzalez J; Conde J; Servicio
       Regional de Alergologia e Inmunologia Clinica,; Hospital Universitario
       Virgen Macarena, Sevilla, Spain.
 SO    Allergol Immunopathol (Madr). 1995 Nov-Dec;23(6):263-6. Unique
       Identifier : AIDSLINE MED/96136350
 AB    Common variable immunodeficiency (CV1) is defined by low serum IgG and
       IgA levels, and it is the second most frequent primary immunodeficiency.
       The indication for treatment with human gammaglobulin in patients with
       this syndrome has been well established. Here we report a case history
       of a patient diagnosed of common variable immunodeficiency, and she had
       treatment with i.v. commercial gammaglobulin. In the course of the
       disease, she developed symptoms that make us think about the possibility
       of hepatitis virus infection. HBV-associated antigens and antibodies,
       and HCV-Ab were all negative. So, amplification of HCV-RNA by polymerase
       chain reaction (PCR) was performed, and it became positive in two
       different determinations. Liver failure got worse quickly and the
       patient died. About the course of the HCV infection, only 30% of
       patients with acute hepatitis get biochemical resolution, and 50-70%
       become carriers and have persistent chronic hepatitis or active chronic
       hepatitis. In this case, HCV infection showed an unusual acute and fatal
       course, it is possible that the impaired immune status of the patient
       could play a role in the acute course of the disease. Therefore, every
       patient who have intravenous immunoglobulin replacement must be
       monitored regularly for liver function tests, and by PCR for HCV
       infection.
 DE    Adult  Case Report  Common Variable
       Immunodeficiency/*COMPLICATIONS/THERAPY  Fatal Outcome  Female
       Hepatitis C/COMPLICATIONS/IMMUNOLOGY/THERAPY/*TRANSMISSION  Hepatitis C
       Antibodies/BLOOD  Hepatitis C Viruses/GENETICS/IMMUNOLOGY/ISOLATION &
       PURIF  Human  IgM/BLOOD/IMMUNOLOGY  Immunoglobulins,
       Intravenous/*ADVERSE EFFECTS/THERAPEUTIC USE  RNA, Viral/BLOOD  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).